Affordable Access

Publisher Website

Spontaneous HCV clearance in a patient with HIV infection and a concurrent, never treated, evolutive HCV hepatitis, after over twenty years of chronic co-infection

Authors
Journal
Retrovirology
1742-4690
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
7
Identifiers
DOI: 10.1186/1742-4690-7-s1-p86
Keywords
  • Poster Presentation
Disciplines
  • Biology
  • Medicine

Abstract

Spontaneous HCV clearance in a patient with HIV infection and a concurrent, never treated, evolutive HCV hepatitis, after over twenty years of chronic co-infection POSTER PRESENTATION Open Access Spontaneous HCV clearance in a patient with HIV infection and a concurrent, never treated, evolutive HCV hepatitis, after over twenty years of chronic co-infection Roberto Manfredi*, Nicola Dentale, Leonardo Calza From 16th International Symposium on HIV and Emerging Infectious Diseases Marseille, France. 24-26 March 2010 Background The reciprocal virological-immunological interactions between HIV and HCV, as well as the reciprocal effect of the specific antiviral therapies, are still poorly known. A rare case report of spontaneous clearance of HCV occurred in an ex-IVDA co-infected with HIV- HCV since 20 years, and never treated for HCV, is presented. Methods A 49-year-old ex-IVDA patient (p) tested HIV-HCV positive since 1989, and was treated for HIV disease since 1990 with limited compliance until 2 years ago. He never attained undetectable HIV viremia until the last 6 months, although CD4+ T-lymphocyte count stea- dily remained >300 cells/μL. Results Until this last semester, against medical recommenda- tion, our p continued alcohol consumption and irregu- lar drug addict, despite an ongoing methadone program. Serum transaminases showed fluctuating values, always >2-3.5-fold normal levels, while HCV replication was confirmed by values of 1,200-4,000 × 103 IU/mL. During the last 6 months, our p first aban- doned its former lamivudine-zidovudine-nevirapine therapy, leading to a combination including 2 novel nucleos(t)ide analogues (tenofovir-emtricitabine), asso- ciated to the protease inhibitors (PI) lopinavir-ritona- vir, and finally in the last 3 months due to gastrointestinal intolerance-hypertriglyceridemia he introduced fosamprenavir-ritonavir on behalf of lopina- vir-ritonavir. Already after lopinavir-ritonavir use, our p attained undetectable plasma HIV-RNA levels (always co

There are no comments yet on this publication. Be the first to share your thoughts.